^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Prostate Cancer
    Drug:Xtandi (enzalutamide) (Androgen receptor inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

    Excerpt:
    ......
    Trial ID:
    RESTORE
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Eur Urol
    Title:

    Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy

    Published date:
    03/27/2021
    Excerpt:
    Targeted biopsies were obtained from 37 men with intermediate- to high-risk prostate cancer before receiving 6 mo of ADT plus enzalutamide...Loss of chromosome 10q (containing PTEN) and alterations to TP53 were predictive of poor response…
    DOI:
    10.1016/j.eururo.2021.03.009